Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road Room 3033, Atlanta, GA 30322, USA; Department of Medicine, Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA 30310, USA. Electronic address: firstname.lastname@example.org.
Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road Room 3033, Atlanta, GA 30322, USA.
Alaska Department of Corrections, 550 West 7th Avenue, Suite 1860, Anchorage, AK 99501, USA.
Institute for Technology Assessment, Massachusetts General Hospital, Harvard University, 101 Merrimac Street, Floor 10, Boston, MA 02114, USA.
Powers Pyles Sutter & Verville PC, 1501 M Street Northwest, Seventh Floor, Washington, DC 20005-1700, USA.
An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing. While high prices for direct-acting antivirals discourage treatment, potential strategies exist to lower prices.